HOC people – Dennis M. Gross, PhD
By David Woods ([email protected]) On January 1st 2006, Dr Dennis Gross retired from Merck after 28 years; the following day, he took up his present position as Associate Dean, Masters…
Details
Letter to the editor
Our HOC People person this month, Dennis M. Gross, PhD, is an associate dean at Thomas Jefferson University where he also teaches courses in pharmacology and toxicology. He emailed us these thoughts on non-adherence.
Details
Making adherence work for your dollar (or pound, or euro…)
By Mary Gabb ([email protected]) As we reported in last month’s HOC, the past few years have witnessed a surge of interest in the role of adherence in health economics research,…
Details
Outsourcing clinical trials
By David Woods ([email protected]) Writing in Pharmatech a couple of years ago, Dr Faiz Kermani observed that “many clinical trials are plagued by delays and setbacks that can cost pharmaceutical…
Details
Rx attracts strong interest at Dublin ISPOR Conference
By Ruth Whittington ([email protected]) The theme of this year’s ISPOR annual European Congress – the largest ever – was ‘Expanding Horizons’, and the Rx team took this very seriously, meeting…
Details
HOC people – Vittorio Maio, PharmD, MPH
By David Woods ([email protected]) Entusiasmo. That’s a word that describes, in his native Italian, what Vittorio Maio brings to his work in health policy and outcomes research. “What makes me…
Details
In-store health clinics: a new approach to primary care?
By David Woods ([email protected]) Health clinics based in retail outlets, particularly drug stores, are changing the way primary care is delivered. Their proponents cite access, convenience, and price transparency as…
Details
How to write a good sentence – length and rhythm
By Clare Gurton ([email protected]) A sentence should not only make sense but should also be capable of standing alone as a complete unit; a good sentence will also have shape…
Details
Understanding study design in comparing drug studies
By Robert Hand ([email protected]) For a variety of reasons, pharmaceutical manufacturers often do not conduct head-to-head studies of their drugs versus the competition. On the other hand, head-to-head studies are…
Details
The “other drug costs” – Part 1: non-adherence
By Mary Gabb ([email protected]) The term “adherence” (or sometimes “compliance”) – the extent to which patients take their treatment as prescribed – has been understood to be a nagging clinical…
Details